Lakewood-Amedex Biotherapeutics, Inc. (LABT) Stock Analysis
A live, multi-source view of Lakewood-Amedex Biotherapeutics, Inc. (LABT): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Lakewood-Amedex Biotherapeutics, Inc.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.
Sector: Healthcare · Industry: Biotechnology · United States · 5 employees · lakewoodamedex.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Lakewood-Amedex Biotherapeutics, Inc. (LABT) had a market capitalization of $4.5M; the shares traded in a 52-week range of $1.66 – $98.20 (-97.8% over the year).
- Market cap
- $4.5M
- Enterprise value
- $-28,091
- Price / book
- 0.94
- EPS (trailing)
- $-3.22
- Payout ratio
- 0.0%
- 52-week range
- $1.66 – $98.20
- 52-week change
- -97.8%
- Average volume
- 1.8M
- Shares outstanding
- 2.4M
- Short % of float
- 4.61%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Lakewood-Amedex Biotherapeutics, Inc. (LABT) last closed at $2.05 (the last completed close before that scan).
Technicals at the scan: RSI 40 (neutral territory), price -8.9% versus its 20-day average, 20-day versus 50-day average spread -3.8%, MACD histogram 0.05.
Sentiment inputs: StockTwits 73% bullish; Reddit mentions -80% over 24 hours.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for LABT in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
LABT has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Lakewood-Amedex Biotherapeutics, Inc. (LABT) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell LABT.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.